Possible association of ACE gene I/D polymorphism with blood pressure - Lowering response to hydrochlorothiazide

Biomedical and Environmental Sciences

Volumn 20, Issue 5, 2007, Pages 351-356

  Zhou, Yong ^a   Wu, Shou Ling ^b   Liu, Hian Qing ^b   Liang, Wan Nian ^c   Liu, Gai Fen ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NORTH CHINA COAL MEDICAL COLLEGE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Genotype; Hypertension; Peptidyl dipeptidase A; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROCHLOROTHIAZIDE;

AGED; ALLELE; ARTICLE; CLINICAL TRIAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED;

AGED; ALLELES; ANTIHYPERTENSIVE AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A;

EID: 37049002877     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Meissner I, Whisnant J, Sheps S (1999). Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension 34, 466-471.
2. Wu S, Hong J, Li H, et al. (2000). No correlation of polymorphism of angiotensin- converting enzyme genes with left ventricular hypertrophy in essential hypertension. Hypertens Res 23, 261-264.
3. Li D, Zhang Y, Ma Y, et al. (1999). Insertion/Deletion Polymorphism of Angiotensin Converting Enzyme Gene in Essential Hypertension and Left Ventricle Hypertrophy in Han Tribe in Shandong Province. Chinese J of Hypertension 7, 35-39.
4. Hypertension Detection and Follow-up Program Cooperative Group. (1979). Five-year findings of the hypertension detection and follow-up programe. II. Mortality by race-sex and age. JAMA 242, 2572-2577.
5. MacMahon S W, Cutler J A, Furberg C D, et al. (1986). The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog in Cardiovasc Dis 29, 99-181.
6. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report (2003). JAMA 289, 2560-2572.
7. Materson B J, Reda D J, Cushman W C (1995). Department of Veterans and Affairs Single-Drug Therapy of Hypertension Study. Revised figures and new data. Am J Hypertens 8, 189-192.
8. Beard K, Bulpitt C, Mascie-Taylor H, et al. (1992). Management of elderly patients with sustained hypertension. Br Med J 304, 412-416.
9. Rigat B, Hubert C, Alhenc-Gelas F, et al. (1990). An insertion/deletion polymorphism in the angiotensin Iconverting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86, 1343-1346.
10. Stavaroulakis G A, Makris T K, Kreisp P G, et al. (2000). Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-enzyme gene polymorphism. Cardiovasc Drugs Ther 14, 427-432.
11. Wu Shouling, Feng Shaoru, Li Kebing, et al. (2001). Correlation of Angiotensin converting enzyme genotype with the effect antihypertensive treatment by Captopril. Chinese Journal of Hypertension 9, 296-297.
12. Sciarrone M T, Stella P, Barlassina C, et al. (2003). ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41, 398-403.
13. Hiraga H, Oshima T, Watanabe M, et al. (1996). Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension 27, 569-572.